U.S. markets closed

InMed Pharmaceuticals Inc. (INM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5000-0.2200 (-8.09%)
At close: 4:00PM EDT
Sign in to post a message.
  • T
    Tom
    I am more than happy buying more at these prices. 😎🤗🚀
  • I
    Iron Sheik
    And right back down to .08. Great acquisition. Market loves it.
  • I
    Iron Sheik
    New 52 week low. Congratulations InMed leadership. The world is your oyster.
  • T
    Tom
    Did Cathie Wood buy today?
  • C
    ChanChan
    Um can you people help me figure this out? What is $2.66 divided by 33? Maybe Tim Swansong can clear this one up with some witty sophmoronic math on a napkin. SAD!
  • r
    rossi
    Just the start 🚀
  • I
    Iron Sheik
    A positive way to look at this announcement is that after all of these years InMed will finally have some patents....one's that they ultimately purchased as they failed to obtain any IP of their own.
  • E
    Etienne
    Reality check. Pre reverse split price now at .10/share. Adams et al all got hundreds of thousands of shares the day after rs. They get shares and pay and you get more fomo
  • C
    ChanChan
    Has anyone seen zooey?
  • r
    rossi
    It’s been a long journey for Inmed there is gonna be some rocket news this year the best is yet to come!
  • R
    Raymond.
    InMed set to Become Major Player in Manufacturing of Rare Cannabinoids
    Emily Cervone
    Mon, June 28, 2021, 6:24 AM

    Image from Shutterstock.

    When it comes to producing rare cannabinoids, the proof is in the process.

    Rare cannabinoids, compounds found in cannabis, have been shown to be potentially effective in creating alternative therapies for diseases with unmet medical needs. They have taken center stage within the cannabis industry, as recent reports state from their biosynthesis will be a $25 billion market by 2025 and $40 billion by 2040.

    Currently, more than 100 cannabinoids have been identified, and early research has shown that they have untapped potential in a variety of industries and health-related sectors, including healthcare (as prescription-based pharmaceuticals), cosmetics, nutraceutical, and with individual consumers.

    However, there is one catch: Standard plant-based extraction of these rare compounds doesn’t tend to be economically viable, therefore synthetic manufacturing is key to success.

    How do companies replicate the compound, then, without compromising the integrity of the product?

    Created by InMed (NASDAQ: INM), a clinical-stage pharmaceutical company, the new manufacturing approach IntegraSyn™ provides a proprietary and cost-effective approach for the manufacturing of rare cannabinoid APIs (active pharmaceutical ingredients). InMed is also the first company to advance the rare cannabinoid, cannabinol (CBN) into a clinical trial as a potential therapeutic to treat diseases with unmet medical needs, including its current studies with skin and ocular diseases. However, it was during the fine-tuning of its biosynthesis program when the IntegraSyn approach was born.

    The truth is that extraction of rare cannabinoids can be prohibitively expensive, chemical synthesis might not produce accurate results, and standard biosynthesis may result in lower yields of cannabinoids in general. However, through IntegraSyn™, these worries are put to rest. Using E. coli biofermentation through its detailed process, to manufacture a highly efficient enzyme as a basic ingredient to manufacture rare cannabinoids, combined with innovative and low-cost upstream processing and downstream purification, an API-grade bioidentical cannabinoid is created. Its flexible yet modular approach allows production to easily shift from one cannabinoid to a range of cannabinoids.

    What does this mean, exactly? Through this optimization, manufacturing costs are lowered and higher yields are produced, a twofold benefit.

    IntegraSyn™’s process yields 5g/L of cannabinoids, far exceeding currently reported industry yields and significantly surpasses the minimal level for commercial viability. Increased yield means a lower price overall, which is vital for pharmaceutical and health/wellness companies so that cannabinoids can be widely accessible and utilized in new products. In light of these new impressive yields InMed is advancing towards another key milestone — producing a commercial-scale batch through a GMP-ready process in the coming months.

    There’s no doubt that significant medical discoveries have been made with the advancement of civilization, and the discovery and use of rare cannabinoids are no exception. Equally as important as the product itself is the process in which it is produced. By creating this novel manufacturing system, it is clear that InMed is positioned to unlock the benefits of rare cannabinoids by building a leading technologically advanced rare-cannabinoid pharmaceutical company.

    See more from Benzinga

    Click here for options trades from Benzinga

    Creative Roots, Fintech Expertise: OLB Group Does it Again

    Pet Pandemic Boom Leads to Preventable Costs, Surrenders

    © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • w
    wizardofahhhs
    All you need to know about InMed....Reverse split on June 29, 2020. Adams awarded 500k shares on June 30, 2020. On June 29, he owned 16k shares after split, then next day he got 500k shares along with all other scam insiders. He's gonne buy lots of astro glide with that money you gave him. Remember him selling all his shares when this farce hit 1.00?
  • C
    ChanChan
    What ever happened to the magnificent biosynthesis with ecoli better then yeast machine? Did they go to the moon and back while i was away? SAD!
  • C
    ChanChan
    What happened to biosynthesis with ecoli? SAD!
  • T
    TrollFinder
    "InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production"
  • r
    rossi
    Doubled down 🔥🏆
  • C
    ChanChan
    Crickets at Inmed. It is dying a slow death it seems
  • I
    Iron Sheik
    Willow News drop......"Our unique biosynthesis process continues to provide high-purity cannabigerol (CBG) with no detectable THC. Production from our first commercial fermentation run is earmarked for sale to prospective customers and we are finalizing agreements with multiple parties." That's how it's done InMed.
  • L
    Long-John
    This got to be in the top 10% of the worst marijuana related investments. It’s an absolute train wreck!
  • D
    DDLT
    what do you guys think about the next 3 - 6 months? more dilution to raise cash? it seems they are making some (not saying good) progress with multiple filings across Europe. atleast they are trying to get somewhere even though it feels like forever with this company...